Doha                                                                                                                                                                                                    07 Jan. 2018

Hamad Medical Corporation (HMC) and the Heidelberg University Hospital in Germany have collaborated to host the first Doha-Heidelberg Research Conference which will take place from January 26 to 27 at the Sheraton Doha.

This is the first research conference between the two organisations and brings together distinguished clinicians,
researchers, and academics to provide a rich programme, which will focus this year on Gastro-Intestinal cancer, neuro-oncology, and haematological malignancies, as well as a second track on paediatric cancers and genomic
newborn screening.

Dr. Saad al-Kaabi, Chairman, Int'l Medical Affairs Office, and conference chair said: “I am delighted
that a long-standing plan to bring such a high-calibre research conference to Qatar has now come to fruition.
“We have built a strong relationship over the years with Heidelberg University Hospital. Many of our physicians
have trained in their world renowned facility and we also have their expert consultants visiting Doha to provide specialist care to some of our patients,” added Dr al-Kaabi.

The conference brings together clinicians, scientists, researchers, and other stakeholders from different
organisations to exchange knowledge and explore new opportunities for clinical and research collaborations. It is
open to anyone from within Qatar’s academic health system as well as healthcare professionals working in the
private sector.

“It’s a special privilege to hear from the eminent Prof Dr. Harald zur Hausen, who is this year’s keynote speaker. Prof zur Hausen, the long-time chair of the Board of the German Cancer Research Centre and honorary
professor at the University of Heidelberg, was awarded the Nobel Prize for medicine in 2008 for his discovery of
the Human Papillomavirus, which can cause cervical cancer,” Dr al-Kaabi added.

This is a unique opportunity for healthcare professionals in Qatar to meet the individual whose research made it
possible to develop a vaccine against cervical cancer, which is the third most common cancer affecting women.

This conference is recognised as an Accredited Group Learning Activity Category 1 as defined by the Qatar Council for Healthcare Practitioners - Accreditation Department. It is a special learning that provides an ideal
platform for doctors, nurses, clinical students, and research academics to share learning, exchange ideas, and promotes professional development.